Comment on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models" - Test2 - elhamkhani - TriplyDB

Comment on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models"

Comment on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models"

http://www.wikidata.org/entity/Q29013008

about

Editorial: preclinical data reproducibility for R&D - the challenge for neuroscience Proteolytic cleavage of apolipoprotein E4 as the keystone for the heightened risk associated with Alzheimer's disease Neuroinflammation in Alzheimer's disease Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models.Opposing effects of Apoe/Apoa1 double deletion on amyloid-β pathology and cognitive performance in APP mice.Synthesis of [(11)C]Bexarotene by Cu-Mediated [(11)C]Carbon Dioxide Fixation and Preliminary PET Imaging.Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway.Complete morphologies of basal forebrain cholinergic neurons in the mouse.Alzheimer's disease: relevant molecular and physiopathological events affecting amyloid-β brain balance and the putative role of PPARs.New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy.Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.Nuclear receptors in neurodegenerative diseases.HDL and cognition in neurodegenerative disorders.Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases.The sleep-wake cycle and Alzheimer's disease: what do we know?Effects of NR1H3 genetic variation on the expression of liver X receptor α and the progression of Alzheimer's disease Improvement of memory deficits and amyloid-β clearance in aged APP23 mice treated with a combination of anti-amyloid-β antibody and LXR agonist RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment.Analysis of differential secondary effects of novel rexinoids: select rexinoid X receptor ligands demonstrate differentiated side effect profiles.Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer's Disease Neuroprotective Effect of Bexarotene in the SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis.Role of Liver X Receptor in AD Pathophysiology.Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease.Bexarotene-Activated Retinoid X Receptors Regulate Neuronal Differentiation and Dendritic Complexity.Liver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient mice Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically.An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Aβ42 aggregates linked with Alzheimer's disease.Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1 ABCA1-Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer's Disease.Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease.RXR controlled regulatory networks identified in mouse brain counteract deleterious effects of Aβ oligomers.Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice.Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"Bexarotene targets autophagy and is protective against thromboembolic stroke in aged mice with tauopathy Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging.Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease.Genome-wide approaches reveal EGR1-controlled regulatory networks associated with neurodegeneration.

P2860

Q24288898-9634D246-86F4-415C-A27B-4034886A40AB Q27011311-77B9D0FE-634D-4DA2-BADB-101925977C23 Q28259238-18F3CF94-EF41-4064-9BED-B0322FC27D17 Q28551351-4761C0D3-1846-4516-B0FB-4BD3D1A6CF71 Q30634663-9600143A-695D-40DA-A074-6FF037CAEF12 Q30703354-7C0D148B-2A5A-4264-ABC8-C0952CA04859 Q33461960-F6AEDE6A-9384-4A10-8C15-C70D1625F158 Q33556068-7CCFA4DF-24CC-4F4E-AD75-10DDB9B5010E Q33676328-B5203910-8D4A-44EA-88E6-7A1FC4DD2513 Q33687237-152A7E60-67E9-4FCF-BA68-A425D5D5C204 Q33959032-5E2BC813-0010-4955-BE34-C5B2E5CDDA80 Q34368970-D5C5D032-AE07-40E1-9058-C666153AA1E6 Q34431008-E8D5DA0F-BE4F-4FE0-9C05-24502BF85A87 Q34580020-F95CEF00-071E-402F-8307-836F6891CD60 Q34614842-BA4F6EC9-8282-4834-9AD6-6593157363EE Q34621541-DD196178-0114-4485-BF63-0BE675C137CC Q34637928-5F960F10-7B9F-48B6-83AA-BF17FF266C91 Q35053654-BE6C7E61-627C-40EA-A809-121CE4B7FDE6 Q35137114-3ADB928B-0B14-4A76-87A3-43372A8A1FA5 Q35662879-BF0B2A9D-381E-432A-AD44-656F6FD085A2 Q35664947-CD92B519-A170-44F0-8356-8A1BB7806E76 Q35749213-997B4F27-1057-4F36-B7B7-F03F8E75806D Q35802822-88038A98-2B65-4FFA-AE36-E63135D8419E Q35882575-358BC7CC-2C6C-43B7-A4AD-65B4E3083C3F Q35946092-90CED7C9-DDB2-44B9-9B2E-F7B4C86B84BA Q35995939-6BE78442-1C15-4386-85E9-B093A7C2FEE3 Q36291665-730FB0A6-AA9B-401A-B038-DE8A6F5F85AB Q36517542-F92DDF66-414E-4126-BFE5-0FC3A6E5D68E Q36575566-49B66411-F3BA-4246-B0B3-18823E696155 Q36593553-AD5FD2E3-54A6-4D17-9612-84F9D01C0682 Q36600444-B7839CAC-199E-44B3-AD11-B6DB459F3ED8 Q36713957-6D9206E9-59AD-4D27-A865-251DF6B4EC05 Q36771721-E679E9B7-2AE3-479F-8060-B9377A064E92 Q36774123-983E516F-6B94-4EA3-B874-65204C3293EA Q36958249-2D2F96C1-0D98-488C-BFB8-FD7304686ADD Q37022972-C85D47E8-0ABE-41CC-A2DC-2A7E8876F3F9 Q37254257-0CDE66AA-6A2F-48B6-B7EC-5BD2A69961B7 Q37395303-422D1177-F351-4DE6-9383-BFA7F920DE33 Q37478496-BDD8B465-9853-4F49-A483-ACA325A40255 Q37610911-E9F126D2-8187-4BD1-BBDB-82ABCA91693C

P2860

Comment on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models"

http://www.wikidata.org/entity/Q29013008

description

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

article publié dans la revue scientifique Science

@fr

artículu científicu espublizáu en 2013

@ast

im Mai 2013 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published in Science

@en

wetenschappelijk artikel (gepubliceerd op 2013/05/23)

@nl

наукова стаття, опублікована в травні 2013

@uk

مقالة علمية (نشرت في 23-5-2013)

@ar

name

Comment on "ApoE-Directed Ther ...... e Deficits in AD Mouse Models"

@ast

Comment on "ApoE-Directed Ther ...... e Deficits in AD Mouse Models"

@en

type

label

Comment on "ApoE-Directed Ther ...... e Deficits in AD Mouse Models"

@ast

Comment on "ApoE-Directed Ther ...... e Deficits in AD Mouse Models"

@en

prefLabel

Comment on "ApoE-Directed Ther ...... e Deficits in AD Mouse Models"

@ast

Comment on "ApoE-Directed Ther ...... e Deficits in AD Mouse Models"

@en

P1433

Q29013008-CBFAC2DD-F57E-47F6-9769-6240344421C9

P1476

Q29013008-4A1B418F-6E2B-4F6F-97BE-2D7959DA8F1C

P2093

Q29013008-1F9714EE-65BA-41D1-BCEA-513A2321E8A9

Q29013008-5FEEEA55-94A5-4EA3-8153-9E9A4EC11E28

Q29013008-7433DE58-99F3-4B0D-8000-34777ED9FD77

Q29013008-D70AC965-8DD1-4538-B038-453B27C4EF5F

P2860

Q29013008-0A46B815-4937-4E0B-B06B-7E0C80517878

Q29013008-13D5EF2C-1EAA-48BB-BAE7-66B7F53AF169

Q29013008-169E8368-809C-4B86-99E8-69DA7F4668D0

Q29013008-2C843A42-76FE-4DC6-8125-D5E6B0600B0A

Q29013008-5BEB695E-D77D-4982-BF59-50B0FD05FBF3

Q29013008-69FB6022-7E13-4665-B048-3F04854C6035

Q29013008-6C34A877-1185-45D1-91CF-538FDA59E764

Q29013008-769BD59A-6B2C-41B4-882B-FA75AC255639

Q29013008-994537F6-5168-4338-83E2-5449B793721A

Q29013008-B8BBECE2-9D9D-466F-BAE9-56951821DF51

P304

Q29013008-7A405CD4-1460-4D50-A5B9-943E71065FE2

P31

Q29013008-49ED5994-0FB8-40F1-9C9D-983EC1851900

P3181

Q29013008-07B83265-CB76-4DD7-85C0-27B2DCDCEE26

P356

Q29013008-FD8CCA89-B5C6-4F55-B496-D1A31A6601C1

P407

Q29013008-E3776294-51D9-47A4-98B4-9FCD9EB5139A

P433

Q29013008-8B72D689-FD87-42DE-9A48-1F28BFACE81D

P478

Q29013008-EB0402A5-7008-434D-AE41-6EBB6CFBAA3E

P577

Q29013008-1A5B90E3-06B9-4377-86A0-EABF6FAFFDF9

P5875

Q29013008-337E8AD9-FAE9-438A-BD71-7D95BBF816EF

P698

Q29013008-A29CBA63-268B-4061-944C-CB74C68CBB88

P932

Q29013008-A3DEE80F-0D9E-45E6-B3FB-1BBDBC602D1A

P3181

P356

SCIENCE.1235809

P1433

P1476

Comment on "ApoE-Directed Ther ...... e Deficits in AD Mouse Models"

@en

P2093

A. A. Cronican

http://www.w3.org/2001/XMLSchema#string

I. Lefterov

http://www.w3.org/2001/XMLSchema#string

N. F. Fitz

http://www.w3.org/2001/XMLSchema#string

R. Koldamova

http://www.w3.org/2001/XMLSchema#string

P2860

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models

ApoE promotes the proteolytic degradation of Abeta

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice.

Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice

The role of apolipoprotein E in Alzheimer's disease.

The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents.

Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease - implications for a new therapeutic approach.

P304

924-924

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2341698

http://www.w3.org/2001/XMLSchema#string

P356

10.1126/SCIENCE.1235809

http://www.w3.org/2001/XMLSchema#string

P407

P433

6135

http://www.w3.org/2001/XMLSchema#string

P478

340

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236909343

http://www.w3.org/2001/XMLSchema#string

P698

23704552

http://www.w3.org/2001/XMLSchema#string

P932

4086452

http://www.w3.org/2001/XMLSchema#string